arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

ProMIS Neurosciences Inc.

PMN
$13.13 ▼ -1.06 (-7.47%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
23 Visible periods
22 Metrics
Absolute Benchmarks
Price Chart
38
Health
Weak
Neutral Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, ProMIS Neurosciences Inc. shows solid but mixed fundamentals, with Return on Invested Capital holding up well. Watch FCF / Net Income against typical quality thresholds. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $120.0M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -19.6%
FCF / Share $-1.14
Trailing P/E
Price / Book 2.4x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

23-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-11.73M
↓ -15.9%
FCF / Share Free cash flow per share
$-1.14
↑ +40.1%

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • Return on Invested CapitalReturn on Invested Capital of 2521.2% is excellent on an absolute basis (target > 10%)
warning

Bearish Risks

  • FCF / Net IncomeFCF / Net Income of 0.71x is caution on an absolute basis (target > 1x)

Health Breakdown

Cash Quality
38

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 6 years · 23 quarters